Drug intelligence / Profile preview

chronvac-c

Development stage: Phase 2
Lead developer: Inovio Pharmaceuticals
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Chronvac-C is a therapeutic DNA vaccine developed for the treatment of chronic hepatitis C virus (HCV) infection. It is designed to stimulate the patient's immune system, particularly T-cell responses, against HCV by encoding non-structural proteins from the virus. Chronvac-C was developed as an alternative to direct-acting antivirals, aiming to induce long-lasting immunity and viral control in patients with chronic hepatitis C. The vaccine was investigated in early-phase clinical trials but has not advanced to late-stage development or approval.

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on chronvac-c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chronvac-c.

Explore the full profile